Loading company…
Velavigo develops multispecific antibodies and antibody-drug conjugates for cancer and autoimmune diseases.
Founded in 2021 in Shanghai, China, by Dr. Jing Li, Velavigo develops antibody-based therapies for oncology and autoimmune diseases. The company uses proprietary platforms to develop multispecific antibodies and antibody-drug conjugates. In July 2025, it closed a pre-Series A+ funding round led by Shunwei Capital Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in